Psychopharmacological Drugs

Iversen, S. and Snyder, S., eds. Handbook of Psychopharmacology Drugs, Neurotransmitters and Behavior. New York Plenum Press, 1977. pp. 333-384. 

Linden, David. The Accidental Mind How brain evolution has given us love, memory, dreams, and God. Cambridge Harvard University Press, 2007. Meyer, Jerrold S., Linda F. Quenzer. Psychopharmacology Drugs, Brain and Behavior. Sinauer, 2005. 

The New England Journal of Medicine asked one of the panel members of the FDA Psychopharmacological Drug Advisory Committee, physician and epidemiologist Thomas B. Newman (2004), to comment on the results of the studies conducted in the controlled clinical trials to determine the risk of suicidality. He wrote,... 

Despite Kapit s function as the chief safety investigator for Prozac, the Division of Psychopharmacological Drug Products, under psychiatrist Paul Leber (see chapter 13), allowed none of Kapit s concerns to appear on the drug s label. The label does not indicate that Prozac is a potentially stimulant drug or that it can cause or worsen depression. 

Food and Drug Administration. (1984, February 24). Transcript of Psychopharmacologic Drugs Advisory Committee 26th Meeting. Rockville, MD Author. 

Pharmaceutical Science Drugs Advisory Committee Psychopharmacologic Drugs Advisory Committee Pulmonary Allergy Drugs Advisory Committee Reproductive Health Drugs Advisory Committee... 

FDA Psychopharmacological Drugs Advisory Committee. Briefing Document of Zeldox Capsules (Ziprasidone HCI) 19 July 2000 www.fda.gov/ohrms/dockets/acOO/backgrd/ 361bla.pdf 19/07/2000. 

Biederman J. New directions in pediatric psychopharmacology. Drug Ther 1982 12 33. 

Meyer, J. S., Quenzer, L. F. (2005). Psychopharmacology Drugs, the brain and behavior. Sunderland, MA Sinauer Associates. 

FDA. FDA briefing document for the Psychopharmacologic Drugs Advisory Committee (meeting), http //www.fda.gov/ohrms/dockets/ac/06/briefing/ 2006-4272bl-01-FDA.pdf, December 13,2006. Accessed August 7,2014. 

U. S. Food and Drug Administration Briefing document for Psychopharmacologic Drugs Advi-... 

Background Package from Pfizer Inc for September 13-14, 2004 Psychopharmacological Drugs Advisory Committee of the Food and Drug Administration, U.S. Food and Drug Administration. 

---